Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.
August 22, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $108.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Axsome Therapeutics. The maintained price target of $108 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100